# Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

> **NCT02528214** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 210 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Oral corticosteroid therapy (prednisone/prednisolone)
- **DRUG:** Inhaled corticosteroid (ICS) therapy
- **DRUG:** Albuterol/Salbutamol
- **DRUG:** Levalbuterol/Levosalbutamol

## Key facts

- **NCT ID:** NCT02528214
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-15
- **Primary completion:** 2017-09-20
- **Final completion:** 2017-11-13
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2019-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02528214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02528214, "Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02528214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*